GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II drugs for Follicular Lymphoma have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GCC-4001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GCC-4001 overview
GCC-4001 (AB-101) is under development for the treatment of rheumatoid arthritis, systemic lupus erythematosus, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis, B-cell non-Hodgkin lymphoma, relapsed or refractory chronic lymphocytic leukemia, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma, Waldenstrom Macroglobulinemia, peripheral T-cell lymphomas (PTCL), angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma (ALCL), R/R classical Hodgkin lymphoma, lupus nephritis (LN) and autoimmune disorders. The therapeutic candidate is an allogeneic, non-engineered, cord blood-derived natural killer (NK) cell therapy. It is administered through intravenous route and is being developed based on AlloNK platform.
Artiva Biotherapeutics overview
Artiva Biotherapeutics is a biotechnology company developing allogeneic natural killer (NK) cell therapies to treat hematologic cancers or solid tumors. It is investigating AB-101, an allogeneic NK cell therapy used for the treatment of B-cell malignancies; AB-201, a CAR-NK (chimeric antigen receptor-modified natural killer) cell therapy targeting HER2 positive solid tumors; and AB-202 against CD19 positive B-cell malignancies. Artiva Biotherapeutics utilizes its proprietary CAR (chimeric antigen receptor) platform to improve NK cells’ therapeutic activity and tumor-targeting capability. Artiva Biotherapeutics is headquartered in San Diego, California, the US.
For a complete picture of GCC-4001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
